In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cetus Oncology Corp.

Division of Novartis AG

Latest From Cetus Oncology Corp.

Amgen’s $125 Per Share Offer For Onyx Reflects Kyprolis Uncertainty

Amgen will acquire the cancer company Onyx for $125 per share, or $10.4 billion. That's higher than the $120 per share Amgen originally offered, but less than some investors and analysts thought obtainable.

BioPharmaceutical Deals

Roche Pounces On Market-Weakened Illumina

Roche’s $5.7 billion hostile takeover offer for Illumina is opportunistic as well as strategic. It is a validation of Illumina’s long-term growth potential but also takes advantage of a depressed stock price due to the global economic slowdown and cutbacks in government funding that have hurt Illumina and other providers of gene sequencing instrumentation.

Medical Device BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • James E Rurka, Pres.
    David Martin, SVP
    Edward F Kenney, VP, Mktg. & Sales
    Frank McCormick, PhD, VP, Research
  • Contact Info
  • Cetus Oncology Corp.
    Phone: (510) 655-8730
    4560 Horton St.
    Emeryville, CA 94608-2916
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register